Allergan (AGN), Mylan (MYL) Sees Short Interest Rise, Gilead (GILD) Fall in Pharma Sector - Guggenheim
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Guggenheim analyst Louise Chen provided a quick analysis of the latest short interest data (09/15/16) in the pharma sector.
The company with the largest decrease in short interest is Gilead (NASDAQ: GILD) at -10.4%.
Mylan, Inc. (NYSE: MYL) short interest up 17.7% to 25,313,358 shares.
Valeant Pharmaceuticals Inc. (NYSE: VRX) short interest up 1.2% to 26,396,945.
Bristol Myers Squibb (NYSE: BMY) short interest up 13.1% to 13,960,166 shares
Endo Pharmaceuticals (NASDAQ: ENDP) short interest up 16.7% to 16,003,377 shares.
Celgene (NASDAQ: CELG) short interest up 18.7% to 6,953,530 shares.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TransDigm (TDG) Valeant Comparison 'Nothing New', Tweet Risk Low and Would Use Weakness to Buy - Credit Suisse
- McDonalds (MCD) volatility increases into Q4 and outlook
- Volatility and Volume movement
Create E-mail Alert Related CategoriesAnalyst Comments, Short Sales, Trader Talk
Related EntitiesLouise Chen, Guggenheim
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!